Seventy-six statements specific to OIT preparatory procedures were included, as well as 71 on the consent information form.
Allergic Disorders
— DRUG MONOGRAPHS BY SUBSECTION —
News and Features
In a recent study, the majority of patients were delabeled with no serious allergic reactions
Participants were asked to rank products in 132 OTC categories.
Findings from initial phase of multifood sublingual immunotherapy.
Authors strongly recommend that clinician performing allergy skin testing or allergen immunotherapy be able to diagnose, manage anaphylaxis.
First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; vitamin D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood glucose.
The approval was based on data from the phase 3, double-blind, placebo-controlled OUtMATCH trial.
The approval of Eohilia was based on data from 2 double-blind, parallel-group, placebo-controlled 12-week phase 3 trials.
The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to ‘1104 for the treatment of eosinophilic esophagitis (EoE). ‘1104 is a first-in-class immunomodulatory peptide derived from Mycobacterium tuberculosis Chaperonin 60.1. The designation is supported by data from the double-blind, placebo-controlled, phase 2a RVLO 121-04 study (ClinicalTrials.gov Identifier: NCT05084963), which evaluated the efficacy and…
Prenatal opioid exposure linked to increased risk for infection, eczema and dermatitis, and asthma in offspring.
Patients controlled on benralizumab can taper inhaled corticosteroids, while maintaining asthma control.
The US Food and Drug Administration (FDA) approved a wide range of therapies in 2023, including many new molecular entities and biological products. The information below is organized by the month in which the product received approval.
Adverse physiologic effect exposure rate highest for increased drug concentrations, CNS depression, QT interval prolongation.
According to the FDA safety alert, health care professionals are recommended to administer promethazine hydrochloride injection via deep IM administration to reduce the risk of severe tissue injury.
Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug accepted for priority review.
The BLA is supported by data from the NIH-funded, phase 3, double-blind, placebo-controlled OUtMATCH trial.
Downward trends during the pandemic seen for Black vs White adults in prevalence and attack rate and for asthma attack rate in children.
ADP101 is an investigational multi-allergen oral immunotherapy designed to simultaneously treat allergy for 1 or more of the most significant food allergens.
- Loading...
